Profile for Japan Patent: 5111517

US Patent Family Members and Approved Drugs for Japan Patent: 5111517

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Dec 11, 2027	Cheplapharm	VALCYTE	valganciclovir hydrochloride
	Dec 11, 2027	Cheplapharm	VALCYTE	valganciclovir hydrochloride

Japan Patent JP5111517: Scope, Claims, and Patent Landscape

Last updated: April 30, 2026

What is JP5111517 and what does it protect?

JP5111517 is a Japan patent publication that appears in the patent family landscape around late-stage pharmacological use and composition claims typical of Japanese filings in the 2010s. However, no claim set, bibliographic data, assignee, title, priority dates, or IPC/CPC classes are provided in the prompt, and the document text is not available in the current context.

Per operating constraints, a complete and accurate scope-and-claims analysis cannot be produced without the actual JP5111517 claim language (and at minimum the publication/filing metadata tied to the specific record).

No analysis is provided.

---

Key takeaways

• JP5111517 scope and claim coverage cannot be analyzed without the patent’s claim text and bibliographic record.
• A reliable landscape (family members, forward/backward citations, freedom-to-operate impact, and claim overlap with competitors) requires document-level data that is not present.

---

FAQs

1. What is the fastest way to analyze JP5111517 claim scope?
2. How do I map JP5111517 claims to FTO risk for Japan?
3. What patent families usually include JP5111517-type claims?
4. How do forward citations typically indicate competitive relevance in Japan?
5. What claim elements drive design-around strategies in method and composition patents in Japan?

---

References

No sources cited because the JP5111517 record and claim text are not available in the provided input.